Accessibility settings

This paper is in the following e-collection/theme issue:

Non-Randomized Study Protocols and Methods (Non-eHealth) (1304) Innovations and Technology in Cancer Care (720) Clinical Cancer Research (262) Prostate Cancer (85) Precision Medicine (456) Cancer Prognosis Models and Machine Learning (145) Medical imaging (208) Cancer genomic data analysis (20)

Published on in Vol 15 (2026)

Preprints (earlier versions) of this paper are available at https://preprints.jmir.org/preprint/86737, first published .
Doctor draws blood from elderly patient's arm in hospital

Liquid Biopsy Biomarkers in Patients With Metastatic Castration-Resistant Prostate Cancer Receiving Prostate-Specific Membrane Antigen Radioligand Therapy: Protocol for a Prospective, Longitudinal Multicenter Observational Study

Liquid Biopsy Biomarkers in Patients With Metastatic Castration-Resistant Prostate Cancer Receiving Prostate-Specific Membrane Antigen Radioligand Therapy: Protocol for a Prospective, Longitudinal Multicenter Observational Study

Authors of this article:

Kerstin Michalski1, 2 Author Orcid Image ;   Theo Lorenzini3 Author Orcid Image ;   Tim Jedamzik1 ;   Marieke Heinrich1 Author Orcid Image ;   Aleksander Kosmala1 Author Orcid Image ;   Isabel Rauscher3 Author Orcid Image ;   Mika Bauch3 Author Orcid Image ;   Lena Reichl4 Author Orcid Image ;   Luisa Amann5 Author Orcid Image ;   Simon Liebl4 ;   Andreas Buck1, 2 Author Orcid Image ;   Matthias Eiber2, 3 Author Orcid Image ;   Constantin Lapa2, 5 Author Orcid Image ;   Rainer Claus2, 4, 6 Author Orcid Image
Article Authors Cited by (1) Tweetations Metrics

Journals

  1. Gambini J. Closing the loop in PSMA radiopharmaceutical therapy for prostate cancer: from eligibility to decision-validated treatment. Frontiers in Medicine 2026;13 View